Soleus Capital Management, L.P. Krystal Biotech, Inc. Transaction History

Soleus Capital Management, L.P.

$1.64 Billion
Q3 2025

A detailed history of Soleus Capital Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 1,018,831 shares of KRYS stock, worth $210 Million. This represents 10.94% of its overall portfolio holdings.

Number of Shares

1,018,831

Previous 922,958 10.39%

Holding current value

$210 Million

Previous $127 Million 41.76%

% of portfolio

10.94%

Previous 9.83%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$134.94 - $176.75 $12.9 Million - $16.9 Million	95,873 Added 10.39%	1,018,831 $180 Million
Q2 2025 Aug 14, 2025	BUY	$123.36 - $181.0 $59.4 Million - $87.1 Million	481,200 Added 108.93%	922,958 $127 Million
Q1 2025 May 15, 2025	BUY	$142.64 - $194.44 $11.9 Million - $16.2 Million	83,379 Added 23.27%	441,758 $79.6 Million
Q4 2024 Feb 14, 2025	BUY	$156.64 - $199.61 $22.1 Million - $28.2 Million	141,400 Added 65.17%	358,379 $56.1 Million
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $15.9 Million - $19.4 Million	90,979 Added 72.21%	216,979 $39.5 Million

Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $6.42 Million - $7.69 Million	41,900 Added 49.82%	126,000 $23.1 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $4.76 Million - $7.91 Million	44,100 Added 110.25%	84,100 $15 Million
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $7.48 Million - $9.99 Million	-77,892 Reduced 66.07%	40,000 $4.96 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $835,527 - $1 Million	7,700 Added 6.99%	117,892 $13.7 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $1.96 Million - $3.26 Million	25,013 Added 29.37%	110,192 $12.9 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $7.46 Million - $8.68 Million	-103,038 Reduced 54.74%	85,179 $6.82 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $1.21 Million - $1.53 Million	-19,115 Reduced 9.22%	188,217 $14.9 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $463,677 - $589,160	-7,150 Reduced 3.33%	207,332 $14.5 Million
Q2 2022 Aug 15, 2022	SELL	$48.93 - $73.47 $3.66 Million - $5.5 Million	-74,855 Reduced 25.87%	214,482 $14.1 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $3.17 Million - $4.39 Million	60,900 Added 26.66%	289,337 $19.3 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $4.1 Million - $9.08 Million	102,908 Added 81.98%	228,437 $16 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $3.02 Million - $4.16 Million	58,000 Added 85.89%	125,529 $6.55 Million
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $6.17 Million - $8.13 Million	-99,315 Reduced 59.53%	67,529 $4.59 Million
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $9.29 Million - $13.4 Million	156,421 Added 1500.73%	166,844 $12.9 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $423,590 - $639,763	10,423 New	10,423 $625,000

Others Institutions Holding KRYS

# of Institutions

325

Shares Held

25M

Call Options Held

241K

Put Options Held

625K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.29B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.

Account

Soleus Capital Management, L.P. Krystal Biotech, Inc. Transaction History